# US 2012/0252741 A1 · Novel semi-synthetic glycopeptides as antibacterial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252741 A1
- Document ID: US20120252741A1
- Status: Published application
- Kind: A1
- Application number: 13/440,692
- Filed: 2012-04-05
- Published: 2012-10-04
- Earliest claimed: 2008-10-24
- Assignees: Biomarin Pharmaceutical Inc.
- Inventors: Daniel Chu; Tao Ye; Bing Wang
- Web page: https://patentgrep.com/patent/US20120252741A1

## CPC

- C07K 9/006: {the peptide sequence being part of a ring structure}
- A61P 31/04: Antibacterial agents
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are semi-synthetic glycopeptides having antibacterial activity. The semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety with certain acyl groups; conversion of the amide group in amino acid-3 to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring to certain substituted amides. Also provided herein are pharmaceutical compositions comprising the semi-synthetic glycopeptides, and methods of use of the semi-synthetic glycopeptides for the treatment and/or prophylaxis of diseases, especially bacterial infections.

## Claims

### Claim 1

A compound having a structure selected from the group consisting of Formulas (I-V):
wherein,
RA is selected from the group consisting of hydrogen, methyl, and C2-C12-alkyl;
R1 and R2 are each independently selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) —C(C═O)R7, and
l) —C(═O)CHR8NR9R10 wherein R8, R9 and R10 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, or R9 and R10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl; or
R1 and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl ring each of which optionally contains one or two hetero functionalities selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, —S—, and S(O)n— wherein n is 1 or 2 and the 3-10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl;
R7 is selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) C1-C12-alkylamino,
l) amino, and
m) amino-cycloalkyl;
X is selected from the group consisting of hydrogen and chlorine;
Y is selected from the group consisting of oxygen and —NR1—;
T is selected from the group consisting of —S(O)2RB, —C(O)RB, and —C(O)NHS(O)2RB;
R is selected from the group consisting of
(1) hydrogen,
(2) cycloalkyl,
(3) cycloalkenyl,
(4) C1-C12-alkyl,
(5) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C1-C12-alkoxy,
(d) C1-C3-alkoxy-C1-C3-alkoxy,
(e) —C(O)OR5 wherein R5 is hydrogen or loweralkyl,
(f) —C(O)NR5R6 wherein R5 and R6 are independently hydrogen or loweralkyl,
(g) amino,
(h) —NR5R6, where R5 and R6 are independently hydrogen or loweralkyl, or R5 and R6 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, C1-C12haloalkyl, and C1-C3-alkoxy-C1-C12-alkyl,
(i) aryl,
(j) substituted aryl,
(k) heteroaryl,
(l) substituted heteroaryl,
(m) mercapto, and
(n) C1-C12-thioalkoxy,
(6) —C(═O)OR11 wherein R11 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, and
(7) —C(═O)NR11R12 wherein R11 and R12 are independently hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R11 and R12 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, substituted loweralkyl, C1-C12haloalkyl, amino, alkylamino, dialkylamino, and C1-C3-alkoxy-C1-C12-alkyl, or
R and its connected oxygen atom taken together is halogen;
R3 is selected from the group consisting of OH, 1-adamantanamino, 2-adamantanamino, 3-amino-1-adamantanamino, 1-amino-3-adamantanamino, 3-loweralkylamino-1-adamantanamino, 1-loweralkylamino-3-adamantanamino, amino, and —NR13R14 wherein R13 and R14 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy; or R13 and R14 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, substituted loweralkyl, C1-C12haloalkyl, amino, alkylamino, dialkylamino and C1-C3-alkoxy-C1-C12-alkyl;
R4 is selected from the group consisting of
(1) —CH2NH—CHR15—(CH2)m—NHS(O)2RB, wherein m is 1 to 6 and R15 is H or loweralkyl,
(2) —CH2NH—CHR15—(CH2)p—C(O)NHS(O)2RB, wherein p is 0 to 6 and R15 is H or loweralkyl,
(3) —CH2NH—CHR15—(CH2)p—C(O)OH, wherein p is 0 to 6 and R15 is H or loweralkyl,
(4) —CH2NRD—CHR15—(CH2)q—NRES(O)2RB, wherein q is 2 to 4 and R15 is H or loweralkyl, RD and RE together represents —CH2—,
(5) H,
(6) —CH2NHCH2PO3H2, and
(7) aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy;
RB is selected from the group consisting of
a) aryl,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) heteroaryl,
j) heterocycloalkyl,
k) aryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C6-alkoxy-C1-C6-alkoxy, amino, amino-C1-C6-alkoxy, C1-C12-alkylamino, C1-C12-alkylamino-C1-C6-alkoxy, C1-C12-dialkylamino, C1-C12-dialkylamino-C1-C6-alkoxy, alkenyl, alkynyl, C1-C12-thioalkoxy, C1-C12-alkyl, C1-C12-substituted alkyl, C1-C12-alkoxy-morpholino, C1-C12-alkoxy-C1-C12-dialkoxyamino, C1-C12-alkoxy-NHS(O)2C1-C6-alkyl, and C1-C12-alkoxy-NHC(O)C1-C6-alkyl; and
l) heteroaryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C6-alkoxy-C1-C6-alkoxy, amino, amino-C1-C6-alkoxy, C1-C12-alkylamino, C1-C12-alkylamino-C1-C6-alkoxy, C1-C12-dialkylamino, C1-C12-dialkylamino-C1-C6-alkoxy, alkenyl, alkynyl, C1-C12-thioalkoxy, C1-C12-alkyl, and C1-C12-substituted alkyl;
RC is each independently selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) —C(═O)R7, and
l) —C(═O)CHR8NR9R10 wherein R8, R9 and R10 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R9 and R10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl;
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound has the Formula I
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound has the Formula II
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound has the Formula III
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound has the Formula IV
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound has the Formula V
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof.

### Claim 7 (depends on 2)

The compound of claim 2, wherein RA is hydrogen or methyl and R4 is hydrogen.

### Claim 8 (depends on 3)

The compound of claim 3, wherein RA is hydrogen or methyl and R4 is hydrogen.

### Claim 9 (depends on 4)

The compound of claim 4, wherein RA is hydrogen or methyl and R4 is hydrogen.

### Claim 10 (depends on 5)

The compound of claim 5, wherein X is hydrogen or chlorine and R4 is hydrogen.

### Claim 11 (depends on 6)

The compound of claim 6, wherein RA is hydrogen or methyl and R4 is hydrogen.

### Claim 12 (depends on 1)

The compound of claim 1, wherein T is hydrogen and R4 is —CH2NH—CHR15—(CH2)m—NHS(O)2RB, wherein m is 1 to 6 and R15 is H or loweralkyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein RA is hydrogen or methyl and T is —S(O)2RB.

### Claim 14 (depends on 1)

The compound of claim 1, wherein RA is hydrogen or methyl and T is —C(O)RB.

### Claim 15 (depends on 1)

The compound of claim 1, wherein RA is hydrogen or methyl and T is —C(O)NHSO2RB.

### Claim 16 (depends on 1)

The compound of claim 1 wherein R3 is each selected from the group consisting of OH, 1-adamantanamino, 2-adamantanamino, 3-amino-1-adamantanamino, 1-amino-3-adamantanamino, 3-loweralkylamino-1-adamantanamino, 1-loweralkylamino-3-adamantanamino, amino and —NR13R14 wherein R13 and R14 are independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy, or R13 and R14 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, substituted loweralkyl, halo-C1-C12-alkyl, amino, alkylamino, dialkylamino, and C1-C3-alkoxy-C1-C12-alkyl.

### Claim 17 (depends on 1)

The compound of claim 1, wherein RB is each selected from the group consisting of
a) aryl,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) heteroaryl,
j) heterocycloalkyl,
k) aryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C6-alkoxy-C1-C6-alkoxy, amino, amino-C1-C6-alkoxy, C1-C12-alkylamino, C1-C12-alkylamino-C1-C6-alkoxy, C1-C12-dialkylamino, C1-C12-dialkylamino-C1-C6-alkoxy, alkenyl, alkynyl, C1-C12-thioalkoxy, C1-C12-alkyl, C1-C12-substituted alkyl, C1-C12-alkoxy-morpholino, C1-C12-alkoxy-C1-C12-dialkoxyamino, C1-C12-alkoxy-NHS(O)2 C1-C6-alkyl, and C1-C12-alkoxy-NHC(O)C1-C6-alkyl; and
l) heteroaryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C6-alkoxy-C1-C6-alkoxy, amino, amino-C1-C6-alkoxy, C1-C12-alkylamino, C1-C12-alkylamino-C1-C6-alkoxy, C1-C12-dialkylamino, C1-C12-dialkylamino-C1-C6-alkoxy, alkenyl, alkynyl, C1-C12-thioalkoxy, C1-C12-alkyl, and C1-C12-substituted alkyl.

### Claim 18 (depends on 7)

The compound of claim 7 wherein R is each selected from the group consisting of
(1) hydrogen,
(2) cycloalkyl,
(3) cycloalkenyl,
(4) C1-C12-alkyl,
(5) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C1-C12-alkoxy,
(d) C1-C3-alkoxy-C1-C3-alkoxy,
(e) —C(O)OR5 wherein R5 is hydrogen or loweralkyl,
(f) —C(O)NR5R6 wherein R6 is hydrogen or loweralkyl,
(g) amino,
(h) —NR5R6, wherein R5 and R6 are independently hydrogen or loweralkyl, or R5 and R6 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, C1-C12haloalkyl, and C1-C3-alkoxy-C1-C12-alkyl,
(i) aryl,
(j) substituted aryl,
(k) heteroaryl,
(l) substituted heteroaryl,
(m) mercapto, and
(n) C1-C12-thioalkoxy,
(6) —C(═O)OR11, wherein R11 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, and
(7) —C(═O)NR11R12, wherein R12 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R11 and R12 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C12-alkyl, substituted loweralkyl, C1-C12haloalkyl, amino, alkylamino, dialkylamino, and C1-C3-alkoxy-C1-C12-alkyl, or
R and its connected oxygen atom taken together is halogen.

### Claim 19 (depends on 9, 10, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 9-10 and 12-17 wherein RC is each independently selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) —C(═O)R7, and
l) —C(═O)CHR8NR9R10 wherein R8, R9 and R10 are independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R9 and R10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl.

### Claim 20 (depends on 8)

The compound of claim 8 wherein R1 and R2 are each independently selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) —C(═O)R7, and
l) —C(═O)CHR8NR9R10 wherein R8, R9 and R10 are independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R9 and R10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl; or
R1 and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl ring which optionally contains one or two hetero functionalities selected from the group consisting of —O—, —NH, —N(C1-C6-alkyl)-, —N(aryl)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, —S—, and S(O)n— wherein n is 1 or 2 and the 3-10 membered heterocycloalkyl ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-C3-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, oxo, C1-C3-alkyl, C1-C3haloalkyl, and C1-C3-alkoxy-C1-C3-alkyl, and
wherein R7 is selected from the group consisting of
a) hydrogen,
b) C1-C12-alkyl,
c) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C1-C12-alkoxy, C1-C3-alkoxy-C1-C3-alkoxy, amino, C1-C12-alkylamino, C1-C12-dialkylamino, alkenyl, alkynyl, and C1-C12-thioalkoxy,
d) C1-C12-alkyl substituted with aryl,
e) C1-C12-alkyl substituted with substituted aryl,
f) C1-C12-alkyl substituted with heteroaryl,
g) C1-C12-alkyl substituted with substituted heteroaryl,
h) cycloalkyl,
i) cycloalkenyl,
j) heterocycloalkyl,
k) C1-C12-alkylamino,
l) amino, and
m) amino-cycloalkyl.

### Claim 21

A compound having the formula selected from the structure formulae consisting of

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, together with a pharmaceutically acceptable carrier or excipient thereof.

### Claim 23 (depends on 1)

A method of treating a mammal in need of such treatment comprising administering to the mammal an antibacterial effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier or excipient thereof.

### Claim 24

A method of making a compound of Formulas I-V, comprising:
modifying a compound from the group consisting of Formulas i, ii, iii, iv and v,
herein RA is hydrogen or methyl, X is chlorine or hydrogen, R3 is OH or alkoxy, 2-adamantanamino, or loweralkylamino as defined herein, R4 is hydrogen or protected —CH2NHCH2PO3H2, or Boc-aminoloweralkyl as defined herein, by a technique selected from the group consisting of
(a) protecting the amino group with 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butoxycarbonyl (Boc), or other appropriate nitrogen protecting groups,
(b) acylating the primary amide group of the 3rd amino acid asparagine with an RBS(O)2Cl, RBC(O)OH with a coupling reagent, or RBS(O)2—NC(O) group in the presence of a base such as triethylamine and the like,
(c) removing the amino protecting group wherein the Boc protecting group is removed with mild acid such as trifluoroacetic acid and Fmoc group is removed with a base such as diethylamine and the like,
(d) if the R3 is alkoxy, removing the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative,
(e) reducing the azide function to an amine,
(f) alkylating the primary alcohol of the mono-sugar or the amino substituent on the amino-substituted sugar moiety of the 4th amino acid of the compound with an alkyl halide having the structure R-J where J is a halogen, R1-J where J is a halogen, R2-J where J is a halogen or RC-J where J is a halogen,
(g) acylating the primary alcohol of the mono-sugar or the amino substituent on the amino-substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure —C(═O)R7,
(h) acylating the primary alcohol of the mono-sugar or the amino substituent on the amino-substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure —C(═O)CHR8NR9R10,
(i) reacting the amino substituent on the amino-substituted sugar moiety of the 4th amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting imine,
(j) conversing the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R3,
(k) phosgene reaction on primary alcohol or primary amine of the mono-sugar moiety of the 4th amino acid of the compound with the adjacent hydroxyl group,
(l) Mannich reaction on the 7th amino acid of the compound where R4 is hydrogen with NH2—CHR15—(CH2)m—NHS(O)2RB, NHRD—CHR15—(CH2)q—NRES(O)2RB, or NH2—CHR15—(CH2)p—C(O)NHSO2RB in the presence of aqueous formaldehyde in acetonitrile and water or other suitable organic solvent,
(m) a combination of (a), (b) and (c),
(n) a combination of (a), (b), (c) and (d),
(o) a combination of (a), (b), (d), (j) and (c),
(p) a combination of (a), (b), (f), and (c),
(q) a combination of (a), (b), (g) and (c),
(r) a combination of (a), (b), (h) and (c),
(s) a combination of (a), (b), (i) and (c),
(t) a combination of (a), (b), (e) and (c),
(u) a combination of (a), (b), (e), (d) and (c),
(v) a combination of (a), (b), (d), (j), (e) and (c),
(w) a combination of (a), (b), (d), (e) and (c),
(x) a combination of (a), (b), (d), (j), (e), (f) and (c),
(y) a combination of (a), (b), (d), (j), (e), (g) and (c),
(z) a combination of (a), (b), (d), (j), (e), (h) and (c),
(aa) a combination of (a), (b), (d), (j), (e), (i) and (c),
(bb) a combination of (a), (b), (d), (e), (f) and (c),
(cc) a combination of (a), (b), (d), (e), (g) and (c),
(dd) a combination of (a), (b), (d), (e), (h) and (c),
(ee) a combination of (a), (b), (d), (e), (i) and (c),
(ff) a combination of (a), (b), (k), and (c),
(gg) a combination of (a), (b), (k), (d), (j) and (c),
(hh) a combination of (a), (b), (e), (k), and (c),
(ii) a combination of (a), (b), (e), (k), (d), (j) and (c),
(jj) a combination of (a), (l), and (c),
(kk) a combination of (a), (j), (l), and (c),
(ll) a combination of (j), (a), (l), and (c),
to form a compound having a formula selected from the group consisting of:
wherein R, R1, R2, R3, R4, RA, X, Y, and T are as defined herein.
